A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
Journal of Rheumatic Diseases
;
: 278-281, 2019.
Article
in English
| WPRIM
| ID: wpr-766189
ABSTRACT
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Spondylitis, Ankylosing
/
Interleukin-17
/
Ear
/
Hearing Loss
/
Neurosyphilis
Limits:
Humans
Language:
English
Journal:
Journal of Rheumatic Diseases
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS